Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVO – Novo Nordisk A/S

Float Short %

0.82

Margin Of Safety %

25

Put/Call OI Ratio

0.71

EPS Next Q Diff

EPS Last/This Y

19.72

EPS This/Next Y

-1.31

Price

46.77

Target Price

60.3

Analyst Recom

2.27

Performance Q

-13.87

Relative Volume

0.89

Beta

0.67

Ticker: NVO




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10NVO45.960.810.401579618
2025-11-11NVO49.170.800.291643519
2025-11-12NVO50.270.790.461685426
2025-11-13NVO49.210.770.271733361
2025-11-14NVO48.110.750.491787813
2025-11-17NVO48.490.770.471710834
2025-11-18NVO47.610.760.571768255
2025-11-19NVO49.020.750.521823587
2025-11-20NVO47.660.740.531870798
2025-11-21NVO47.650.740.701927598
2025-11-24NVO45.220.710.561684222
2025-11-25NVO470.710.511754353
2025-11-26NVO48.730.700.581774482
2025-12-01NVO48.440.720.461677518
2025-12-02NVO47.480.720.381698555
2025-12-03NVO47.630.710.351730780
2025-12-04NVO480.710.821747737
2025-12-05NVO47.930.710.571758528
2025-12-08NVO46.80.710.451675450
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10NVO45.94-6.91049.423.48
2025-11-11NVO49.15-6.91857.222.90
2025-11-12NVO50.27-6.9743.022.90
2025-11-13NVO49.15-7.4-1046.522.87
2025-11-14NVO48.25-7.4-1405.922.87
2025-11-17NVO48.48-7.4-695.322.87
2025-11-18NVO47.53-7.4-1187.023.10
2025-11-19NVO49.00-7.4-206.423.10
2025-11-20NVO47.59-7.4-663.323.10
2025-11-21NVO47.64-7.4-716.823.10
2025-11-24NVO44.99-7.4-1579.423.10
2025-11-25NVO47.06-7.4506.023.10
2025-11-26NVO48.69-7.4294.523.10
2025-12-01NVO48.43-7.5-1167.523.10
2025-12-02NVO47.43-7.4-1414.223.11
2025-12-03NVO47.57-7.4-952.423.11
2025-12-04NVO48.00-7.5-1359.523.11
2025-12-05NVO47.86-7.5-1416.323.08
2025-12-08NVO46.77-7.5- 23.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10NVO0.00-1.930.79
2025-11-11NVO0.00-1.930.79
2025-11-12NVO0.00-1.930.84
2025-11-13NVO0.00-1.930.84
2025-11-14NVO0.00-1.930.84
2025-11-17NVO0.00-1.660.84
2025-11-18NVO0.00-1.660.84
2025-11-19NVO0.00-1.660.84
2025-11-20NVO0.00-1.660.84
2025-11-21NVO0-1.660.84
2025-11-24NVO0-0.750.84
2025-11-25NVO0-0.750.84
2025-11-26NVO0-0.750.82
2025-12-01NVO0-1.570.82
2025-12-02NVO0-1.570.82
2025-12-03NVO0-1.570.82
2025-12-04NVO0-1.570.82
2025-12-05NVO0-1.570.82
2025-12-08NVO0-1.580.82
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

1.02

Avg. EPS Est. Current Quarter

5.87

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-1.58

Beta

0.67

Average Sales Estimate Current Quarter

77293

Average Sales Estimate Next Quarter

76155

Fair Value

58.33

Quality Score

98

Growth Score

79

Sentiment Score

31

Actual DrawDown %

68.4

Max Drawdown 5-Year %

-68.5

Target Price

60.3

P/E

13.62

Forward P/E

13.05

PEG

2.12

P/S

3.37

P/B

7.77

P/Free Cash Flow

15.75

EPS

3.43

Average EPS Est. Cur. Y​

23.26

EPS Next Y. (Est.)

21.94

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

32.76

Relative Volume

0.89

Return on Equity vs Sector %

34.2

Return on Equity vs Industry %

24.8

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

-0.33

EBIT Estimation

Novo Nordisk A/S
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 78554
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
stock quote shares NVO – Novo Nordisk A/S Stock Price stock today
news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch NVO – Novo Nordisk A/S yahoo finance google finance
stock history NVO – Novo Nordisk A/S invest stock market
stock prices NVO premarket after hours
ticker NVO fair value insiders trading